Ipriflavone is a synthetic flavonoid
(isoflavone) derived from the soy compound
Where is it found?
Ipriflavone does occur naturally in food but only in trace amounts. It is available as a
Ipriflavone has been used
in connection with the following conditions (refer to the individual
health concern for complete information):
Who is likely to be deficient?
As ipriflavone is not an essential nutrient, no deficiency state exists.
How much is usually taken?
The typical supplemental amount of ipriflavone is 200 mg three times daily. Taking 300 mg
twice daily has been reported to be just as effective as 200 mg three times per
Are there any side effects or interactions?
In a trial of ipriflavone for osteoporosis, 29 of the 132 women in the ipriflavone group
completing the three-year trial developed a clinically significant drop in
lymphocytes.2 These cells, which make up approximately 22 to 28% of the white blood
cells in the normal adult, are critical components of the immune system and its ability to
respond to viral infections. In some of these women, a return to normal levels took almost two
years after they had stopped the ipriflavone. Since this finding has been reported in one
other smaller clinical trial,3 it suggests that women choosing to take ipriflavone
should have their lymphocytes measured regularly by their doctor.
In double-blind studies, the frequency of perceived side effects in ipriflavone-treated
people (14.5%) was actually less than that observed in people receiving the placebo
(16.1%).4 Side effects were mainly mild stomach upset. Researchers recommend that patients
with severe kidney disease take a lower amount of ipriflavone (200 to 400 mg
Are there any drug
Certain medicines may interact with ipriflavone. Refer to drug interactions for a list of those medicines.
1. Acerbi D, Poli G, Ventura P. Comparative bioavailability of two oral
formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different
dosage schemes. Eur J Drug Metabol Pharmacokinet 1998,23:172–7.
2. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the
treatment of postmenopausal osteoporosis. JAMA 2001;285:1482–8.
3. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established
osteoporosis and long-term safety. Calcif Tissue Int 1997;61:23–27.
4. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established
osteoporosis and long-term safety. Calcif Tissue Int 199:61:S23–7 [includes
5. Rondelli I, Acerbi D, Ventura P. Steady-state pharmacokinetics of
ipriflavone and its metabolites in patients with renal failure. Int J Clin Pharm Res